课题基金 / 基金详情

Precision medicine for diabetic Individuals: a joint Malaysia-UK Effort (PRIME) project

Precision medicine for diabetic Individuals: a joint Malaysia-UK Effort (PRIME) project
糖尿病患者的精准医疗:马来西亚-英国联合努力 (PRIME) 项目
批准号:
MR/T018186/1
负责人:
Chim Lang
金额:
$24.52万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Malaysia has the highest rate of diabetes in Asia and one of the highest in the world. Adding to this problem is the growing number of obese Malaysian children and adolescents who are now or will be affected by diabetes. The harmful effects of diabetes on the vasculature or blood vessels dominate the complications caused by diabetes. These vascular effects affect the heart (to cause heart attack, stroke and heart failure), feet (leading to amputations), eyes (to cause blindness) and kidneys (to cause kidney failure). This escalating diabetes pandemic with its cardiovascular complications has huge effects both for the affected individual and their society. Despite sugar-lowering diabetic drugs and control of other cardiovascular risk factors, people with diabetes continue to succumb to the cardiovascular-related diseases. While efforts are being made to combat this diabetic epidemic through public health measures, new strategies are clearly needed to address and prevent the cardiovascular complications of diabetes. In the UK, we have pioneered the concept of personalised medicine through the use of genetics to determine who will and will not respond to commonly used drugs in diabetes, as well as for heart protective drugs such as those that lower blood pressure and cholesterol. We have also made substantial inroads in the use of artificial intelligence to analyse digital pictures of patients' retinas to find features that reveal a patient's current disease status and is predictive of future risk of complications such as stroke and heart disease. However, the majority of these studies on how diabetes and the cardiovascular complications arise and how patients respond to medications are from white European ancestry populations despite the fact that diabetes in Europeans is very different to diabetes in Asians. There is therefore an urgent need for detailed research into the specific causes and cardiac consequences of diabetes in Asians including those in Malaysia in order to identify the processes that drive the onset of cardiovascular complications of diabetes that exist in Malaysian ethnicities and use this to understand how best to manage diabetes in Malaysia. In our proposed PRIME partnership, we propose to build upon the precision medicine expertise in Dundee that includes the on-going £7 million NIHR Global Health Research Unit on Global Diabetes Outcomes Research INdia-Scotland Partnership for Precision medicine in Diabetes - INSPIRED (https://inspired-nihr.com/) project that is exploring specific differences in combinations of genomic, retinal and clinical determinants of complications of diabetes and therapeutic response between Scottish and the South Indian population. The plan is to embed insights from the on-going INSPIRED program into the PRIME project that will add value to each project. Using the available precision medicine expertise in Dundee, we will facilitate knowledge transfer to Malaysia for initial establishment of a similar concept using the Malaysian government initiated The Malaysian Cohort (TMC) study, that is the biggest and most comprehensive population-based cohort study in Malaysia. The overarching objective of the PRIME project is to develop an international collaboration between Dundee and Malaysia that will establish the potential for translation of precision medicine to management of diabetes and its associated cardiovascular complications in Malaysia.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/ccr3.3888
发表时间: 2021-03
期刊: Clinical case reports
影响因子: 0.7
作者: [Noyes JD, Mordi IR, Zeb Q, Lang CC]
通讯作者: Lang CC
Prediction of Major Adverse Cardiovascular Events From Retinal, Clinical, and Genomic Data in Individuals With Type 2 Diabetes: A Population Cohort Study.
根据 2 型糖尿病患者的视网膜、临床和基因组数据预测主要不良心血管事件:一项群体队列研究。
DOI: 10.2337/dc21-1124
发表时间: 2022
期刊: Diabetes care
影响因子: 16.2
作者: [Mordi IR]
通讯作者: Mordi IR
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
SGLT2 抑制剂的降血糖和代谢作用。
DOI: 10.1016/j.hfc.2022.03.004
发表时间: 2022
期刊: Heart failure clinics
影响因子: 3.4
作者: [Mordi IR]
通讯作者: Mordi IR
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Singh 等人关于文章“恩格列净对 2 型糖尿病或糖尿病前期和射血分数降低的心力衰竭 (SUGAR-DM-HF) 患者左心室容量的影响”的信函。
DOI: 10.1161/circulationaha.120.053057
发表时间: 2021
期刊: Circulation
影响因子: 37.8
作者: [Singh JS]
通讯作者: Singh JS
7
    国内基金
    海外基金
    新型二维/三维双体系癌症研究模型的建立
    • 批准号:
      32070796
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2020
    • 负责人:
      王霞
    • 依托单位:
    Chinese Journal of Integrative Medicine
    • 批准号:
      81224004
    • 项目类别:
      专项基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2012
    • 负责人:
      徐浩
    • 依托单位:
    基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
    基于循证医学本体论的临床元数据语言研究